TITLE

Alliances & Licensing Update

PUB. DATE
August 2010
SOURCE
PharmaWatch: Cancer;Aug2010, Vol. 9 Issue 8, p12
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
The article offers news briefs related to strategic alliances in pharmaceutical companies. The drug development company Aeterna Zentaris Inc. has collaborated with Almac Diagnostic to develop cancer diagnostic. Bayer Schering Pharma AG has formed a strategic alliance with OncoMed Pharmaceuticals Inc. for stem cell cancer therapeutics. The biopharmaceutical company Molecular Templates Inc. has entered a research collaboration with ImClone Systems Inc.
ACCESSION #
53752276

 

Related Articles

  • OncoMed, Bayer Schering Ally for Anticancer Stem Cell R&D.  // Chain Drug Review;7/19/2010, Vol. 32 Issue 12, p61 

    The article reports on the international strategic alliance formed by Bayer Schering Pharma AG and OncoMed Pharmaceuticals Inc. to develop, discover and market novel anti-cancer stem cell therapeutics.

  • OncoMed's Wnt Deal Adds $40M Up Front.  // Bioworld Week;6/21/2010, Vol. 18 Issue 25, p5 

    The article reports that Redwood City, California-based OncoMed Pharmaceuticals Inc. secured a 40 million-worth early stage deal with Berlin's Bayer Schering Pharma AG to develop a drug targeting the Wnt signaling pathway.

  • OncoMed Has 'Wnt' in its Sails; Bayer Deal Adds $40M Up Front. Boggs, Jennifer // BioWorld Today;6/18/2010, Vol. 21 Issue 117, p1 

    The article reports on the deal reached by OncoMed Pharmaceuticals Inc. with Bayer Schering Pharma AG in June 2010 to develop drugs targeting the Wnt signaling pathway. It briefly cites a similar deal signed by OncoMed with GlaxoSmithKline plc in 2007. Included in the deal with Bayer are five...

  • European pharma consolidation generates quality spinoffs. Sheridan, Cormac // Nature Biotechnology;Dec2006, Vol. 24 Issue 12, p1458 

    The article focuses on the consolidation and acquisition of European pharmaceutical companies. The article discuses that Berlin based Schering company and two German companies are acquired by Bayer Healthcare, Germany, to establish Bayer-Schering Pharma. And the establishment will concentrate on...

  • Bayer Schering Pharma to Set Up R&D Center in China. Ramesh, Deepti // Chemical Week;3/2/2009, Vol. 171 Issue 6, p19 

    The article reports on the plan of Bayer Schering Pharma to establish a global research and development (R&D) center in Beijing China. Andreas Fibig, chairman of Bayer's board of management says they are continuously increasing their presence in the Asia/Pacific region where China is their key...

  • AEterna Partners with Sanofi in $165M BPH Deal.  // Bioworld Week;3/16/2009, Vol. 17 Issue 11, p2 

    The article reports on the partnership of Quebec, Canada-based AEterna Zentaris Inc. and Bridgewater, New Jersey-based Sanofi-Aventis US LLC. The deal between them costs more than $165 million and authorizes Sanofi-Aventis to be AEterna's official licensee of its lead product cetrorelix, a...

  • SWOT Analysis.  // Schering AG SWOT Analysis;Jun2007, p5 

    A business analysis of Bayer Schering Pharma AG, a global pharmaceutical company that is active in areas such as gynecology, andrology, oncology, diagnostic imaging and specialized therapeutics, is provided, focusing on its strengths, weaknesses, opportunities for improvement and threats to the...

  • OTHER NEWS TO NOTE.  // BioWorld International;2/11/2009, Vol. 14 Issue 6, p3 

    This section offers news briefs on the biotechnology industries. Ablynx NV will receive milestone payments totaling €3 million from Boehringer Ingelheim as part of its strategic alliance for the development and commercialization of Nanobodies. Affimed Therapeutics AG entered into a...

  • NICE recommends all patients admitted to hospital are risk assessed for VTE.  // Operating Theatre Journal;Feb2010, Issue 233, p3 

    The article announces the launching of Bayer Schering Pharma AG with its implementation toolkit for the prevention of Venous Thromboembolism (VTE) in Great Britain.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics